நோயெதிர்ப்பு மெய்நிகர் ஆண்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோயெதிர்ப்பு மெய்நிகர் ஆண்டு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோயெதிர்ப்பு மெய்நிகர் ஆண்டு Today - Breaking & Trending Today

Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients


Press release content from Business Wire. The AP news staff was not involved in its creation.
Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients
February 26, 2021 GMT
WILMINGTON, Del. (BUSINESS WIRE) Feb 26, 2021
Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful 1 reduction in the annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. 2 The results were presented at the American Academy of Asthma Allergy & Immunology Virtual Annual Meeting. 2
Tezepelumab, a potential first-in-class medicine, when added to standard of care (SoC) achieved a 56% reduction (p 0.001) in AAER over 52 weeks in the overall patient population, compared to placebo when added to SoC. 2 SoC was medium- or high-dose inhaled corticosteroids (ICS) plus at ....

United States , Brendan Mcevoy , Michele Meixell , Drug Administration Breakthrough Therapy Designation , American Academy , Asthma Allergy , Immunology Virtual Annual , North America , Systemic Lupus Erythematosus , Business Wire , Corporate News , Health Care Industry , Product Testing , Clinical Trials , Pharmaceutical Manufacturing , Lung Disease , Diseases And Conditions , Drug Trials , Diagnosis And Treatment , Products And Services , Medical Biotechnology Industry , Medical Research , ஒன்றுபட்டது மாநிலங்களில் , பிரெண்டன் அம்கிவாய் , அமெரிக்கன் கலைக்கழகம் , ஆஸ்துமா ஒவ்வாமை ,